Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Total Liabilities for 13 consecutive years, with $182.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 7.23% to $182.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $182.8 million, a 7.23% increase, with the full-year FY2024 number at $178.6 million, changed N/A from a year prior.
  • Total Liabilities was $182.8 million for Q3 2025 at Theravance Biopharma, down from $201.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $748.3 million in Q1 2021 to a low of $165.6 million in Q4 2022.
  • A 5-year average of $342.2 million and a median of $178.6 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 76.57% in 2023, then grew 19.51% in 2025.
  • Theravance Biopharma's Total Liabilities stood at $726.7 million in 2021, then crashed by 77.21% to $165.6 million in 2022, then increased by 1.12% to $167.5 million in 2023, then rose by 6.66% to $178.6 million in 2024, then increased by 2.33% to $182.8 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Total Liabilities are $182.8 million (Q3 2025), $201.2 million (Q2 2025), and $177.6 million (Q1 2025).